|Dr. Leslie S. Sloan Ph.D.||Chief Operating Officer||626.94k||N/A||1971|
|Mr. Michael C. Hanley M.B.A.||Chief Commercial Officer & Chief Bus. Officer||577.42k||N/A||1973|
|Mr. James Paul Kastenmayer J.D., Ph.D.||Interim CEO, Pres & Gen. Counsel||N/A||N/A||1972|
|Mr. Jonathan D. Alspaugh M.B.A.||CFO & Principal Accounting Officer||N/A||N/A||1983|
|Ms. Cortney Caudill M.B.A.||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Joey Perrone||VP of Fin. & Investor Relations||N/A||N/A||N/A|
|Dr. Kelly Boothe Ph.D.||Sr. Director of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Eugene Sackett||VP of HR||N/A||N/A||N/A|
|Dr. Eric Bradford M.B.A., M.D., M.Sc.||Chief Devel. Officer||N/A||N/A||N/A|
|Dr. Josie Gayton Ph.D.||Sr. VP of Program Strategy, Operations & Chief of Staff||N/A||N/A||N/A|
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Aeglea BioTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.